

**Glenmark Pharmaceuticals Inc., USA launches
Authorized Generic to Milnacipran Hydrochloride Tablets,
12.5 mg, 25 mg, 50 mg, and 100 mg**

Elmwood Park, New Jersey, March 19, 2026 – Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch¹ of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg. Glenmark’s Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella®² Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg.

According to IQVIA™ sales data for the 12-month period ending January 2026, the Savella® Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg market² achieved annual sales of approximately \$102.9 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are excited to announce the launch of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg, the authorized generic to Savella® Tablets. This launch further strengthens our commitment to bring to market quality and affordable alternatives for patients.”

¹Glenmark’s Milnacipran Hydrochloride Tablets is only approved for the indication(s) listed in Glenmark’s approved label.

²All brand names and trademarks are the property of their respective owners.

³Market includes brand and all available therapeutic equivalents. Note: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmark’s product is only approved for the indications listed in Glenmark’s approved label and is not marketed for all RLD indications.

*IQVIA™ National Sales Perspectives: Retail & Non-Retail, January 2026

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research-led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and

oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com.

For more information, please contact:

In the U.S.:	In India:
Akhila Natarajan mediarelations@glenmarkpharma.com +91 98216 89525	Akhila Natarajan mediarelations@glenmarkpharma.com +91 98216 89525
Danielle Hagen, Nahigian Strategies danielle@nahigianstrategies.com 202-365-6112	Adfactors PR glenmark@adfactorspr.com +91 88502 91322